Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (41-50 of 234) with videos related to

Pageof 24
Sort By:
Communications Biology|October 2, 2018
Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancerMatti Annala, Sinja Taavitsainen, Gillian Vandekerkhove, et al.
Investigational New Drugs|August 28, 2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)Sunil Parimi, Misha Eliasziw, Scott North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancerKim N Chi, Martin E Gleave, Ladan Fazli, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancerBernhard J C Eigl, Scott E Eggener, Jenny Baybik, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 1, 2018
A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completionSunil Parimi, Erica Tsang, Abraham Alexander, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2021
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE studyGiulia Baciarello, Mustafa Özgüroğlu, Suneel Mundle, et al.
European Urology|September 21, 2024
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic ReviewEdoardo Francini, Neeraj Agarwal, Elena Castro, et al.
Cancer|January 8, 2009
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerDaniel Y C Heng, Kim N Chi, Nevin Murray, et al.
Pageof 24

Showing results (41-50 of 234) with videos related to

Sort By:
Pageof 24
Communications Biology|October 2, 2018
Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancerMatti Annala, Sinja Taavitsainen, Gillian Vandekerkhove, et al.
Investigational New Drugs|August 28, 2016
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)Sunil Parimi, Misha Eliasziw, Scott North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancerKim N Chi, Martin E Gleave, Ladan Fazli, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancerBernhard J C Eigl, Scott E Eggener, Jenny Baybik, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 1, 2018
A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completionSunil Parimi, Erica Tsang, Abraham Alexander, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2021
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE studyGiulia Baciarello, Mustafa Özgüroğlu, Suneel Mundle, et al.
European Urology|September 21, 2024
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic ReviewEdoardo Francini, Neeraj Agarwal, Elena Castro, et al.
Cancer|January 8, 2009
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerDaniel Y C Heng, Kim N Chi, Nevin Murray, et al.
Pageof 24